Variations in opioid receptor genes in neonatal abstinence syndrome

Drug and Alcohol Dependence

Volumn 155, Issue , 2015, Pages 253-259

  Wachman, Elisha M ^a   Hayes, Marie J ^b   Sherva, Richard ^c   Brown, Mark S ^d   Davis, Jonathan M ^e   Farrer, Lindsay A ^c   Nielsen, David A ^f  

^a BOSTON MEDICAL CENTER   (United States)

^b UNIVERSITY OF MAINE   (United States)

^c BOSTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d EASTERN MAINE MEDICAL CENTER   (United States)

^e TUFTS MEDICAL CENTER   (United States)

^f BAYLOR COLLEGE OF MEDICINE   (United States)

Author keywords

Genetics; Neonatal abstinence syndrome (NAS); Opioids; Single nucleotide polymorphisms (SNPs)

Indexed keywords

OPIATE RECEPTOR; CATECHOL METHYLTRANSFERASE; COMT PROTEIN, HUMAN; DELTA OPIATE RECEPTOR; KAPPA OPIATE RECEPTOR; MU OPIATE RECEPTOR; OPRD1 PROTEIN, HUMAN; OPRK1 PROTEIN, HUMAN; OPRM1 PROTEIN, HUMAN; PREPRONOCICEPTIN; PROTEIN PRECURSOR;

ALLELE; ARTICLE; CONTROLLED STUDY; DISEASE SEVERITY; FEMALE; GENE; GENETIC ASSOCIATION; GENETIC VARIABILITY; GENOTYPE; HUMAN; LENGTH OF STAY; MAJOR CLINICAL STUDY; MALE; MICROARRAY ANALYSIS; NEWBORN; OPIATE RECEPTOR GENE; OPRD1 GENE; OPRM1 GENE; PREDICTION; PRIORITY JOURNAL; SINGLE NUCLEOTIDE POLYMORPHISM; WITHDRAWAL SYNDROME; GENETICS; INFANT; NEONATAL ABSTINENCE SYNDROME;

CATECHOL O-METHYLTRANSFERASE; FEMALE; HUMANS; INFANT; INFANT, NEWBORN; LENGTH OF STAY; MICROARRAY ANALYSIS; NEONATAL ABSTINENCE SYNDROME; POLYMORPHISM, SINGLE NUCLEOTIDE; PROTEIN PRECURSORS; RECEPTORS, OPIOID; RECEPTORS, OPIOID, DELTA; RECEPTORS, OPIOID, KAPPA; RECEPTORS, OPIOID, MU;

EID: 84941940639     PISSN: 03768716     EISSN: 18790046     Source Type: Journal    
DOI: 10.1016/j.drugalcdep.2015.07.001     Document Type: Article

References (48)

1. Backes C.H., Backes C.R., Gardner D., Nankervis C.A., Giannone P.J., Cordero L. Neonatal abstinence syndrome: transitioning methadone-treated infants from an inpatient to an outpatient setting. J. Perinatol. 2012, 32:425-430. 10.1038/jp.2011.114.
2. Bagley S.M., Wachman E.M., Holland E., Brogly S.M. Review of the assessment and management of neonatal abstinence syndrome. Addict. Sci. Clin. Pract. 2014, 9:19. 10.1186/1940-0640-9-19.
3. Bauer I.E., Soares J.C., Nielsen D.A. The role of opioidergic genes in the treatment outcome of drug addiction pharmacotherapy: a systematic review. Am. J. Addict. 2015, 24:15-23. 10.1111/ajad.12172.
4. Beuten J., Payne T.J., Ma J.Z., Li M.D. Significant association of catechol-O-methyltransferase (COMT) haplotypes with nicotine dependence in male and female smokers of two ethnic populations. Neuropsychopharmacology 2006, 31:675-684.
5. Brown M.S., Hayes M.J., Thornton L.M. Methadone versus morphine for treatment of neonatal abstinence syndrome: a prospective randomized clinical trial. J. Perinatol. 2015, 35:278-283. 10.1038/jp.2014.194.
6. Bruchas M.R., Land B.B., Chavkin C. The dynorphin/kappa opioid system as a modulator of stress-induced and pro-addictive behaviors. Brain Res. 2010, 1314:44-45. 10.1016/j.brainres.2009.08.062.
7. Culpepper-Morgan J.A., Kreek M.J. Hypothalamic-pituitary-adrenal axis hypersensitivity to naloxone in opioid dependence: a case of naloxone-induced withdrawal. Metabolism 1997, 46:130-134.
8. Desai R.J., Hernandez-Diaz S., Bateman B.T., Huybrechts K.F. Increase in prescription opioid use during pregnancy among Medicaid-enrolled women. Obstet. Gynecol. 2014, 123:997-1002.
9. Gelernter J., Kranzler H.R., Sherva R., et al. Genome-wide association study of opioid dependence: multiple associations mapped to calcium and potassium pathways. Biol. Psychiatry 2014, 76:66-74. 10.1016/j.biopsych.2013.08.034.
10. Gerra G., Leonardi C., Cortese E., D'Amore A., Lucchini A., Strepparola G., Serio G., Farina G., Magnelli F., Zaimovic A., Mancini A., Turci M., Manfredini M., Donnini C. Human kappa opioid receptor gene (OPRK1) polymorphism is associated with opiate addiction. Am. J. Med. Genet., B: Neuropsychiatr. Genet. 2007, 144:771-777.
11. Goldman D., Oroszi G., Ducci F. The genetics of addiction: uncovering the genes. Focus 2006, 6:401-415.
12. Hall E.S., Wexelblatt S.L., Crowley M., Grow J.L., Jasin L.R., Klebanoff M.A., McClead R.E., Meinzen-Derr J., Mohan V.K., Stein H., Walsh M.C. A multicenter cohort study of treatments and hospital outcomes in neonatal abstinence syndrome. Pediatrics 2014, 134:e527-e534. OCHNAS Consortium. 10.1542/peds.2013-4036.
13. Hodgkinson C.A., Qiaoping Y., Xu K., Shen P.H., Heinz E., Lobos E.A., Binder E.B., Cubells J., Ehlers C.L., Gelernter J., Mann J., Riley B., Roy A., Tabakoff B., Todd R.D., Zhou Z., Godman D. Addictions biology: haplotype-based analysis for 130 candidate genes on a single array. Alcohol Alcohol. 2008, 43:505-515.
14. Hosak L. Role of the COMT gene Val158Met polymorphism in mental disorders: a review. Eur. Psychiatry 2007, 22:276-281. 10.1093/alcalc/agn032.
15. Hudak M.L., Tan R.C. Neonatal drug withdrawal. Pediatrics 2012, 129:e540-e560. American Academy of Pediatrics, Committee on Fetus and Newborn, Committee on Drugs. 10.1542/peds.2011-3212.
16. Ittiwut R., Listman J.B., Ittiwut C., Cubelis J.F., Weiss R.D., Brady K., Oslin D., Farrer L.A., Kranzler H.R., Gelernter J. Association between polymorphisms in catechol-O-methyltransferase (COMT) and cocaine-induced paranoia in European-American and African-American populations. Am. J. Med. Genet., B: Neuropsychiatr. Genet. 2011, 156B:651-660. 10.1002/ajmg.b.31205.
17. Lee J., Hulman S., Musci M., Stang E. Neonatal abstinence syndrome: influence of a combined inpatient/outpatient methadone treatment regimen on the average length of stay of a Medicaid NICU population. Popul. Health Manage. 2015, (March (24)). (Epub ahead of print).
18. Jansson L.M., Velez M., Harrow C. The opioid-exposed newborn: assessment and pharmacologic management. J. Opioid Manage. 2009, 5:47-55.
19. Jones H.E., Kaltenbach K., Heil S.H., et al. Neonatal abstinence syndrome after methadone or buprenorphine exposure. N. Engl. J. Med. 2010, 363:2320-2331. 10.1056/NEJMoa1005359.
20. Klepstad P., Dale O., Skorpen F., Borchgrevink P.C., Kaasa S. Genetic variability and clinical efficacy of morphine. Acta Anaesthesiol. Scand. 2005, 49:902-908.
21. Koob G., Kreek M.J. Stress, dysregulation of drug reward pathways, and the transition to drug dependence. Am. J. Psychiatry 2007, 164:1149-1159.
22. Kreek M.J., Bart G., Lilly C., LaForge K.S., Nielsen D.A. Pharmacogenetics and human molecular genetics of opiate and cocaine addiction and their treatments. Pharmacol. Rev. 2006, 57:1-26.
23. Kumar D., Chakraborty J., Das S. Epistatic effects between variants of kappa-opioid receptor gene and A118G of mu-opioid receptor gene increase susceptibility to addiction in Indian population. Prog. Neuropsychopharmacol. Biol. Psychiatry 2012, 36:225-230. 10.1016/j.pnpbp.2011.10.018.
24. Landau R., Liu S.K., Blouin J.L., Carvalho B. The effect of OPRM1 and COMT genotypes on the analgesic response to intravenous fentanyl labor analgesia. Anesth. Analg. 2013, 116:386-391. 10.1213/ANE.0b013e318273f2c7.
25. Levran O., Yuferov V., Kreek M.J. The genetics of the opioid system and specific drug addictions. Hum. Genet. 2012, 131:823-842. 10.1007/s00439-012-1172-4.
26. Levran O., Londono D., O'Hara K., Nielsen D.A., Peles E., Rotrosen J., Casadonte P., Linzy S., Randesi M., Ott J., Adelson M., Kreek M.J. Genetic susceptibility to heroin addiction; a candidate-gene association study. Genes Brain Behav. 2008, 7:720-729. 10.1111/j.1601-183X.2008.00410.x.
27. Li C.Y., Zhou W.Z., Zhang P.W., Johnson C., Wei L., Ulh G.R. Meta-analysis and genome-wide interpretation of genetic susceptibility to drug addiction. BMC Genomics 2011, 12:508. 10.1186/1471-2164-12-508.
28. Lind J.N., Petersen E.E., Lederer P.A., Phillips-Bell G.S., Perrine C.G., Li R., Hudak M., Correia J.A., Creanga A.A., Sappenfield W.M., Curran J., Blackmore C., Watkins S.M., Anjohrin S. Infant and maternal characteristics in neonatal abstinence syndrome-selected hospitals in Florida, 2010-2011. MMWR Morb. Mortal. Wkly. Rep. 2015, 64:213-216. CDC.
29. Logan B.A., Brown M.S., Hayes M.J. Neonatal abstinence syndrome: treatment and pediatric outcomes. Clin. Obstet. Gynecol. 2013, 56:186-192. 10.1097/GRF.0b013e31827feea4.
30. Lotsch J., Starke C., Liefhold J., Geisslinger G. Genetic predictors of the clinical response to opioid analgesics: clinical utility and future perspectives. Clin. Pharmacokinet. 2004, 43:983-1013.
31. Mague S.D., Blendy J.A. OPRM1 SNP (A118G): involvement in disease development, treatment response, and animal models. Drug Alcohol Depend. 2010, 108:172-182. 10.1016/j.drugalcdep.2009.12.016.
32. Nelson E.C., Lynskey M.T., Heath A.C., Wray N., Agrawal A., Shand F.L., Henders A.K., Wallace L., Todorov A.A., Schrage A.J., Madden P.A., Degenhardt L., Martin N.G., Montgomery G.W. Association of OPRD1 polymorphisms with heroin dependence in a large case-control series. Addict. Biol. 2014, 19:111-121. 10.1111/j.1369-1600.2012.00445.x.
33. Pap D., Gonda X., Molnar E., Lazary J., Benko A., Downey D., Thomas E., Chase D., Toth Z.G., Mekli K., Platt H., Payton A., Elliott R., Anderson I.M., Deakin J.F., Bagdy G., Juhasz G. Genetic variants in the catechol-o-methyltransferase gene are associated with impulsivity and executive function: relevance for major depression. Am. J. Med. Genet., B: Neuropsychiatr. Genet. 2012, 159B:928-940. 10.1002/ajmg.b.32098.
34. Patrick S.W., Schumacher R.E., Benneyworth B.D., Krans E.E., McAllister J.M., Davis M.M. Neonatal abstinence syndrome and associated health care expenditures: United States, 2000-2009. JAMA 2012, 307:1934-1940. 10.1001/jama.2012.3951.
35. Pritham U.A. Breastfeeding promotion for management of neonatal abstinence syndrome. J. Obstet. Gynecol. Neonatal Nurs. 2013, 42:517-526. 10.1111/1552-6909.12242.
36. Pritham U.A., Paul J.A., Hayes M.J. Opioid dependency in pregnancy and length of stay for neonatal abstinence syndrome. J. Obstet. Gynecol. Neonatal Nurs. 2012, 41:180-190. 10.1111/j.1552-6909.2011.01330.x.
37. Rakvag T.T., Klepstad P., Baar C., Kvarn T.M., Dale O., Kaasa S., Krokan H.E., Skorpen F. The Val158Met polymorphism of the human catechol-O-methyltransferase (COMT) gene may influence morphine requirements in cancer pain patients. Pain 2005, 116:73-78.
38. Reyes-Gibby C.C., Shete S., Rakvag T., Bhat S.V., Skorpen F., Bruera E., Kaasa S., Klepstad P. Exploring joint effects of genes and the clinical efficacy of morphine for cancer pain. OPRM1 and COMT gene. Pain 2007, 130:25-30.
39. Sankar S., Donn S.M. Management of neonatal abstinence syndrome in neonatal intensive care units: a national survey. J. Perinatol. 2006, 26:15-77.
40. U.S.Department of Health and Human Services, Substance Abuse and Mental Health Administration Results from the 2013 National Survey on Drug Use and Health: National Findings 2013, 〈http://www.samhsa.gov/data/sites/default/files/NSDUHresultsPDFWHTML2013/Web/NSDUHresults2013.pdf〉.
41. Wachman E.M., Hayes M.J., Lester B.M., Terrin N., Brown M.S., Nielsen D.A., Davis J.M. Epigenetic variation in the mu-opioid receptor gene in infants with neonatal abstinence syndrome. J. Pediatr. 2014, 65:472-478. 10.1016/j.jpeds.2014.05.040.
42. Wachman E.M., Hayes M.J., Brown M.S., Paul J., Harvey-Wilkes K., Terrin N., Huggins G.S., Aranda J.V., Davis J.M. Association of OPRM1 and COMT single nucleotide polymorphisms with hospital length of stay and treatment of neonatal abstinence syndrome. JAMA 2013, 309:1821-1827. 10.1001/jama.2013.3411.
43. Wachman E.M., Newby P.K., Vreeland J., Byun J., Bonganzi A., Bauchner H., Philipp B.L. The relationship between maternal opioid agonists and psychiatric medications on length of hospitalization for neonatal abstinence syndrome. J. Addict. Med. 2011, 5:293-299. 10.1097/ADM.0b013e3182266a3a.
44. Wang S.C., Tsou H.H., Chung R.H., Chang Y.S., Fang C.P., Chen C.H., Ho I.K., Kuo H.W., Liu S.C., Shih Y.H., Wu H.Y., Huang B.H., Lin K.M., Chen A.C., Hsiao C.F., Liu Y.L. The association of genetic polymorphisms in the k-opioid receptor 1 gene with body weight, alcohol use, and withdrawal symptoms in patients with methadone maintenance. J. Clin. Psychopharm. 2014, 34:205-211. 10.1097/JCP.0000000000000082.
45. Xu K., Seo D., Hodgkinson C., Hu Y., Goldman D., Sinha R. A variant on the kappa opioid receptor gene (OPRK1) is associated with stress response and related drug craving, limbic brain activation and cocaine relapse risk. Transl. Psychiatry 2013, 3:e292. 10.1038/tp.2013.62.
46. Xuei X., Flury-Wetherill L., Almasy L., Bierut L., Tischfield J., Schuckit M., Numberger J.I., Foroud T., Edenberg H.J. Association analysis of genes encoding the nociceptin receptor (OPRL1) and its endogenous ligand (PNOC) with alcohol or illicit drug dependence. Addict. Biol. 2008, 13:80-87.
47. Yuferov V., Fussell D., LaForge K.S., Nielsen D.A., Gordon D., Ho A., Leal S.M., Ott J., Kreek M.J. Redefinition of the human kappa opioid receptor gene (OPRK1) structure and association of haplotypes with opiate addiction. Pharmacogenetics 2004, 14:793-804.
48. Zhang H., Kranzler H.R., Yang B.Z., Luo X., Gelernter J. The OPRD1 and OPRK1 loci in alcohol or drug dependence: OPRD1 variation modulates substance dependence risk. Mol. Psychiatry 2008, 13:531-543.